Abstract

POS0231 SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
E067 Bimekizumab maintained efficacy responses through 52 weeks in biologic disease-modifying antirheumatic drugnaïve patients with psoriatic arthritis who were responders at week 16: results from BE OPTIMAL, a phase 3, activereference study
William R Tillett ... Yoshiya Tanaka
Rheumatology (Oxford, England) | VOL. 63
William R Tillett, et. al.William R Tillett ... Yoshiya Tanaka
24 Apr 2024
E069 Bimekizumab maintained efficacy responses through 52 weeks in patients with psoriatic arthritis and inadequate response or intolerance to tumour necrosis factor inhibitors who were responders at week 16: results from a phase 3, randomised study
William R Tillett ... Dennis Mcgonagle
Rheumatology (Oxford, England) | VOL. 63
William R Tillett, et. al.William R Tillett ... Dennis Mcgonagle
24 Apr 2024
AB1099 SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR
L Coates ... A M Orbai
Annals of the Rheumatic Diseases | VOL. 82
L Coates, et. al.L Coates ... A M Orbai
30 May 2023
OP0255 BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BE COMPLETE, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDY
J F Merola ... A Asahina
Annals of the Rheumatic Diseases | VOL. 81
J F Merola, et. al.J F Merola ... A Asahina
23 May 2022
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Racial variability in immune responses only partially explains differential systemic sclerosis disease severity
Kamini E Kuchinad ... Ami A Shah
Annals of the Rheumatic Diseases | VOL. -
Kamini E Kuchinad, et. al.Kamini E Kuchinad ... Ami A Shah
17 Jul 2024
Early identification of rheumatoid arthritis: does it induce treatment-related cost savings?
Elise Van Mulligen ... Annette Van Der Helm-Van Mil
Annals of the Rheumatic Diseases | VOL. -
Elise Van Mulligen, et. al.Elise Van Mulligen ... Annette Van Der Helm-Van Mil
17 Jul 2024
Altered CD8+ T cell subpopulation in the bone marrow microenvironment of cynomolgus monkeys with spontaneous ankylosing spondylitis
Tangming Guan ... Wende Li
Annals of the Rheumatic Diseases | VOL. -
Tangming Guan, et. al.Tangming Guan ... Wende Li
17 Jul 2024
Dysregulation of immune checkpoint molecules as a characteristic of autoimmune congenital heart block
Ana-Luisa Stefanski ... Thomas Dörner
Annals of the Rheumatic Diseases | VOL. -
Ana-Luisa Stefanski, et. al.Ana-Luisa Stefanski ... Thomas Dörner
12 Jul 2024
View more papers